Continuing a long tradition of research and pioneering advances in preventive cardiovascular medicine, Penn's Preventive Cardiovascular Program leads the development and evaluation of novel therapeutic, diagnostic, and prognostic approaches to atherosclerotic disease. Patients may be eligible for any clinical trial if certain criteria is met.
Clinical trials in which we are currently enrolling patients include:
Abnormal LDL-cholesterol
NICE Study
The NICE study is a clinical research study to assess the effects of obicetrapib, an investigational drug, on lipoprotein metabolism in people with LDL-cholesterol levels between 100 and 190 mg/dL.
Participation in the study will last for approximately 11-18 weeks. It will involve a screening visit to assess your eligibility, two overnight, inpatient visits during which you will undergo a lipid metabolism study involving an infusion over 12 hours, eating multiple small meals, and having blood drawn several times through an IV (intravenous) catheter, and 3 short outpatient visits for follow-up labs.
You will be compensated for each study visit after the screening visit if you qualify and enroll in the study. You will receive $2300 if you complete the entire study.
Abnormal triglycerides
ISIS 678354-CS6
A study of olezarsen administered subcutaneously to patients with severe hypertriglyceridemia.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study with up to approximately 390 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the study will be approximately 78 weeks, which includes an up to 12-week screening period, a 53-week treatment period, and a 13-week post-treatment evaluation period or transition to open-label extension (OLE) study with up to 1-year treatment.
Eligible participants must have fasting triglyceride levels ≥ 500 mg/dL at both Screening and Qualification visits.